489446-42-6

Basic information

• Product Name: 4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID
• Synonyms: 4-(Aminomethyl)benzeneboronicacid,N-BOCprotected97%;4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID;4-(AMINOMETHYL)BENZENEBORONIC ACID, N-BOC PROTECTED;4-(TERT-BUTOXYCARBONYLAMINOMETHYL)PHENYLBORONIC ACID;4-(Aminomethyl)benzeneboronic acid, N-BOC protected 97%;N-BOC-4-(AMINOMETHYL)BENZENEBORONIC ACID;4-(Boc-aMinoMethyl)benzeneboronic acid, 97%;[4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]boronic acid
• CAS NO: 489446-42-6
• Molecular Formula: C₁₂H₁₈BNO₄
• Molecular Weight: 251.09
• Product Categories: Boronate Ester;Boronic Acid;Potassium Trifluoroborate;blocks;BoronicAcids;Amino;Aryl;Organoborons
• Mol File: 489446-42-6.mol

Chemical Properties

• Melting Point: 208-210°C
• Appearance: /
• Density: 1.15 g/cm³
• Refractive Index: 1.526
• Storage Temp.: Keep Cold
• PKA: 8.54±0.16(Predicted)
• CAS DataBase Reference: 4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID(489446-42-6)
• EPA Substance Registry System: 4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID(489446-42-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 489446-42-6(Hazardous Substances Data)

Usage

Uses

Used in Biomimetic Membranes:
4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID is used as a key component in the preparation of lipid pore-filled silica thin-film membranes. These membranes are designed for the biomimetic recovery of diluted carbohydrates, leveraging the selective binding properties of the boronic acid group to target specific carbohydrate molecules.
Used in Proteomics Research:
In the field of proteomics, 4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID serves as a valuable reagent for the study of proteins and their interactions. 4-((N-BOC-AMINO)METHYL)PHENYLBORONIC ACID's boronic acid functionality allows for the selective capture and analysis of glycoproteins, which are proteins with attached carbohydrate moieties. This selective binding is crucial for the identification and characterization of glycoproteins in complex biological samples.

InChI:InChI=1/C12H18BNO4/c1-12(2,3)18-11(15)14-8-9-4-6-10(7-5-9)13(16)17/h4-7,16-17H,8H2,1-3H3,(H,14,15)

Upstream product

• 87199-17-5 4-formylphenylboronic acid, 
• 4248-19-5 tert-butyl carbazate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 51239-46-4 4-(aminomethyl)phenylboronic acid 

Downstream Products

• 1371630-29-3 methyl 8-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)-1-cyclopropyl-9-methyl-4-oxo-4H-quinolizine-3-carboxylate 
• 1371630-31-7 ethyl 8-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-3-carboxylate 
• 508224-95-1 8-(4-(aminomethyl)phenyl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-quinolizine-3-carboxylic acid 
• 1374454-11-1 {4-[3-chloro-5-fluoro-2-(5-methyl-[1,3,4]oxadiazol-2-yl)-indol-1-yl]-benzyl}-carbamic acid tert-butyl ester 
• 1374452-62-6 {4-[5-fluoro-2-(3-methyl-[1,2,4]oxadiazol-5-yl)-indol-1-yl]-benzyl}-carbamic acid tert-butyl ester 
• 1374452-60-4 1-[4-(tert-butoxycarbonylamino-methyl)-phenyl]-3-chloro-4-fluoro-1H-indole-2-carboxylic acid methyl ester 
• 1374452-57-9 {4-[3-chloro-5-methoxy-2-(5-methyl-[1,2,4]oxadiazol-3-yl)-indol-1-yl]-benzyl}-carbamic acid tert-butyl ester 
• 1374452-35-3 1-[4-(tert-butoxycarbonylamino-methyl)-phenyl]-3-chloro-5-methoxy-1H-indole-2-carboxylic acid methyl ester 
• 1374262-89-1 tert-butyl 4-(2-phenyl-9H-benzo[f]imidazo[1,2-d]pyrido[2,3-b][1,4]diazepin-3-yl)benzylcarbamate 
• 1216894-51-7 Tert-butyl 3-(1-(tert-butoxycarbonyl)-4-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-6-(4-((tert-butoxycarbonylamino)methyl)phenyl)-1H-indazole-1-carboxylate 
• 945235-39-2 N-(4′-(aminomethyl)-6-methylbiphenyl-3-yl)-1-(benzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamide 
• 945240-16-4 1-(benzo[d][1,3]dioxol-5-yl)-N-(6-methyl-4'-(propionamidomethyl)biphenyl-3-yl)cyclopropanecarboxamide 
• 945241-81-6 1-(benzo[d][1,3]dioxol-5-yl)-N-(6-methyl-4'-(propylsulfonamidomethyl)biphenyl-3-yl)cyclopropanecarboxamide 

Relevant articles and documents

Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands

Cell surface biomarkers such as prostate-specific membrane antigen (PSMA) and hepsin have received considerable attention as targets for imaging prostate cancer (PCa) due to their high cell surface expression in such tumors and easy access for imaging pro

Synthesis method of 4-amino methylphenylboronic acid hydrochloride

The invention discloses a synthesis method of 4-amino methylphenylboronic acid hydrochloride, and belongs to the field of organic synthesis. According to the method, 4-formyl phenylboronic acid is used as an initial raw material and is condensed with tert-butyl carbamate, and the 4-amino methylphenylboronic acid hydrochloride is generated through three steps of reactions of reduction and Boc removal. According to the method, imine is synthesized through condensation with 4-formyl phenylboronic acid, then sodium borohydride is reduced, and finally deprotection and salification are carried out, so that direct high-pressure hydrogenation in literatures is avoided, the yield is obviously increased, and meanwhile, the process reproducibility is good.

QUINOXALINE COMPOUNDS AND USES THEREOF

This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.

Compounds with medicinal effects due to interaction with the glucocorticoid receptor

The invention provides for compounds having the structure according to the formula I

Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors

Various thienopyrimidine-based analog compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.